NASDAQ · LNTH

Lantheus Holdings, Inc.

$108.03 +$3.21 (+3.06%) 1D After hours
Charting by TradingView

Key Metrics

$6.82B
Market cap
24.46×
P/E · TTM
$1.55B
Revenue · TTM
$279.03M
Net income
EPS · TTM $3.90
Dividend yield —
Free cash flow —
Beta · 1Y 0.41
EBITDA · TTM $452.82M
Gross margin 60.5%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 22
    The stock moved +9.0% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 22
  • Mar 9
    The stock moved +10.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Mar 9

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$6.82B
Enterprise value$6.90B
Shares outstanding65.1M
52-wk range$47.25 – $111.86
Avg volume · 20D989.3K
Net cash −$71.83M
Book value / share$16.96
IndustryIn Vitro & In Vivo Diagnostic Substances
ExchangeNASDAQ
About Lantheus Holdings, Inc.
IPO dateJun 25, 2015
Employees1193

Lantheus Holdings Inc is a radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver patient outcomes. The Company classifies its products into Radiopharmaceutical Oncology, Precision Diagnostics, and Strategic Partnerships and Other Revenue.

Wolf Grade COMING SOON

—

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E24.46
P/S4.41
P/FCF—
EV/EBITDA15.23
EV/Sales4.46
Graham №$38.61

Profitability

Gross 60.5%
Operating 24.2%
Net 18.0%
FCF —
ROE / ROIC 24.3% · 21.7%

Financial Health

Current ratio2.83
Quick ratio2.64
Debt / equity0.47
Debt / EBITDA 1.26
Net cash −$71.83M
Working capital$609.12M

Cash Flow · TTM

Operating CF $407.71M
Capex —
Free cash flow —
Buybacks —
Dividends paid —
Shareholder yield —

Piotroski F-Score

4 / 9
Middling fundamentals · 4 of 9 signals passing

Altman Z-Score

5.6
Safe zone (> 2.99) · bankruptcy risk negligible

Graham Number vs Price

$38.61 vs $108.03
Trades 2.8× above classic defensive value — priced for growth
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings